Hepatitis C Phase 3 Trials Underway for TMC435

Share

Follow Us

Print this page

Medivir Announces New Studies in Phase III Program for TMC435

HUDDINGE, Sweden, March 13, 2012 /PRNewswire via COMTEX/ — Study in previous non-responder Hepatitis C genotype-1 infected patients

Study in Hepatitis C genotype-4 infected patients

MedivirAB (omx:MVIR) a research based specialty pharmaceutical company focused on infectious diseases announces that its oral, once daily investigational protease inhibitor TMC435, developed by Janssen Pharmaceuticals for the treatment of Hepatitis C virus (HCV), has commenced patient dosing and started screening in two new phase III clinical trials, HPC3001 and HPC3011, respectively.

Continue reading this entire article:

http://www.marketwatch.com/story/medivir-announces-new-studies-in-phase-iii-program-for-tmc435-2012-03-13

Download Our Free Reports

Inside you'll discover:

• Things You May Not Know About Hepatitis C
• 7 Liver Detox SUPER Foods Your Doctor Isn't Telling You About
• 5 Dangerous Foods That Will Wreak Havoc On Your Liver
• A free "Mystery" Gift Valued at $9.99

Email address

Download Now

You'll also receive the latest news and information to support liver health.
Rest assured, we will not rent your email to anyone.